CL2021000152A1 - Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 - Google Patents

Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1

Info

Publication number
CL2021000152A1
CL2021000152A1 CL2021000152A CL2021000152A CL2021000152A1 CL 2021000152 A1 CL2021000152 A1 CL 2021000152A1 CL 2021000152 A CL2021000152 A CL 2021000152A CL 2021000152 A CL2021000152 A CL 2021000152A CL 2021000152 A1 CL2021000152 A1 CL 2021000152A1
Authority
CL
Chile
Prior art keywords
interleukin
inhibitors
activity
sulfonylurea compounds
nlrp3
Prior art date
Application number
CL2021000152A
Other languages
English (en)
Inventor
Matthew Volgraf
Craig Stivala
Jeffrey A Stafford
James M Veal
Lynnie Lin Trzoss
Christopher Mcbride
Richard M Pastor
Steven Thomas Staben
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2021000152A1 publication Critical patent/CL2021000152A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente divulgación se refiere a compuestos de sulfonilurea y compuestos relacionados útiles en el tratamiento de un trastorno sensible a la modulación de citocinas tales como IL-1ß e IL-18, modulación de NLRP3 o inhibición de la activación de NLRP3 o componentes relacionados del proceso inflamatorio.
CL2021000152A 2018-07-20 2021-01-19 Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 CL2021000152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862701358P 2018-07-20 2018-07-20

Publications (1)

Publication Number Publication Date
CL2021000152A1 true CL2021000152A1 (es) 2021-07-09

Family

ID=67515207

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000152A CL2021000152A1 (es) 2018-07-20 2021-01-19 Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1

Country Status (20)

Country Link
US (1) US11560391B2 (es)
EP (1) EP3823726A1 (es)
JP (1) JP7411631B2 (es)
KR (1) KR20210034588A (es)
CN (1) CN112437683A (es)
AR (1) AR117617A1 (es)
AU (1) AU2019305095A1 (es)
BR (1) BR112021001012A2 (es)
CA (1) CA3104199A1 (es)
CL (1) CL2021000152A1 (es)
CO (1) CO2021000817A2 (es)
CR (1) CR20210024A (es)
IL (1) IL280139A (es)
MA (1) MA53170A (es)
MX (1) MX2021000660A (es)
PE (1) PE20211049A1 (es)
PH (1) PH12020552155A1 (es)
SG (1) SG11202012159TA (es)
TW (1) TW202019937A (es)
WO (1) WO2020018970A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47308A (fr) 2017-01-23 2019-11-27 Genentech Inc Composés chimiques comme inhibiteurs de l'activité interleukine-1
RU2020110219A (ru) 2017-08-15 2021-09-17 Инфлазоум Лимитед Сульфонилмочевины и сульфонилтиомочевины в качестве ингибиторов nlrp3
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
EP3986879A1 (en) 2019-06-21 2022-04-27 AC Immune SA Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators
CN117105890A (zh) * 2019-11-12 2023-11-24 成都百裕制药股份有限公司 酰胺衍生物及其制备方法和在医药上的应用
WO2021255279A1 (en) 2020-06-19 2021-12-23 Ac Immune Sa D i h yd rooxazo le and thiourea derivatives modulating the nlrp3 inflammasome pathway
WO2023118521A1 (en) 2021-12-22 2023-06-29 Ac Immune Sa Dihydro-oxazol derivative compounds
US20230279026A1 (en) * 2022-02-21 2023-09-07 Viva Star Biosciences (Suzhou) Co., Ltd. Novel bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity
WO2024013395A1 (en) 2022-07-14 2024-01-18 Ac Immune Sa Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
US20240101563A1 (en) 2022-07-28 2024-03-28 Ac Immune Sa Novel compounds

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216026A (en) 1990-07-17 1993-06-01 Eli Lilly And Company Antitumor compositions and methods of treatment
SK283679B6 (sk) 1997-01-29 2003-11-04 Pfizer Inc. Deriváty sulfonylmočoviny
EP1214087A1 (en) 1999-09-14 2002-06-19 Pfizer Products Inc. Combination treatment with il-1ra and compounds that inhibit il-1 processing and release
MXPA04002565A (es) 2001-11-30 2004-05-31 Pfizer Prod Inc Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
EP2538978B1 (en) * 2010-02-22 2016-09-07 RaQualia Pharma Inc. Use of an ep4 receptor antagonist in the treatment of allergic contact dermatitis and psoriasis
EP2781216A4 (en) 2011-09-02 2015-05-27 Kyowa Hakko Kirin Co Ltd CHEMOKINREZEPTORAKTIVITÄTSREGLER
MA41553B1 (fr) * 2015-02-16 2020-04-30 The Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy & Undiv Sulfonylurées, composés apparentés, et leur utilisation
SG11201806745RA (en) 2016-02-16 2018-09-27 Univ Queensland Sulfonylureas and related compounds and use of same
AU2017254523B2 (en) 2016-04-18 2021-09-02 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
WO2017184604A1 (en) 2016-04-18 2017-10-26 Ifm Therapeutics, Inc Compounds and compositions for treating conditions associated with nlrp activity
MA47308A (fr) 2017-01-23 2019-11-27 Genentech Inc Composés chimiques comme inhibiteurs de l'activité interleukine-1
AU2017416068A1 (en) 2017-05-24 2019-10-31 The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Novel compounds and uses
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
DK3661925T3 (da) 2017-07-07 2022-02-28 Inflazome Ltd Hidtil ukendte sulfonamidcarboxamidforbindelser
EP3668601A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
US20210122739A1 (en) 2017-08-15 2021-04-29 Inflazome Limited Novel sulfonamide carboxamide compounds
RU2020110219A (ru) 2017-08-15 2021-09-17 Инфлазоум Лимитед Сульфонилмочевины и сульфонилтиомочевины в качестве ингибиторов nlrp3
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
TW201910314A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
WO2019092172A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
US20200354341A1 (en) 2017-11-09 2020-11-12 Inflazome Limited Novel sulfonamide carboxamide compounds
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
GB201803394D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
CN112584899A (zh) 2018-07-03 2021-03-30 诺华股份有限公司 Nlrp调节剂
WO2020010118A1 (en) 2018-07-03 2020-01-09 Novartis Inflammasome Research, Inc. Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist
JP7320595B2 (ja) 2018-07-20 2023-08-03 エフ． ホフマン－ラ ロシュ アーゲー インターロイキン－１活性の阻害剤としてのスルホンイミドアミド化合物
AR117951A1 (es) 2018-07-20 2021-09-08 Gruenenthal Gmbh Derivados de triazolquinoxalina adicionalmente sustituidos
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
KR20210053910A (ko) 2018-08-15 2021-05-12 인플라좀 리미티드 신규한 설폰아마이드유레아 화합물
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
JP2022505525A (ja) 2018-10-24 2022-01-14 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
WO2020154321A1 (en) 2019-01-22 2020-07-30 Novartis Inflammasome Research, Inc. Compounds and compositions for treating conditions associated with nlrp activity
WO2021002887A1 (en) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy

Also Published As

Publication number Publication date
CR20210024A (es) 2021-02-22
TW202019937A (zh) 2020-06-01
AR117617A1 (es) 2021-08-18
KR20210034588A (ko) 2021-03-30
SG11202012159TA (en) 2021-01-28
MX2021000660A (es) 2021-03-25
MA53170A (fr) 2021-05-26
CA3104199A1 (en) 2020-01-23
PE20211049A1 (es) 2021-06-04
JP2021530536A (ja) 2021-11-11
AU2019305095A1 (en) 2020-12-17
BR112021001012A2 (pt) 2021-04-20
EP3823726A1 (en) 2021-05-26
US20210261568A1 (en) 2021-08-26
US11560391B2 (en) 2023-01-24
CO2021000817A2 (es) 2021-02-17
CN112437683A (zh) 2021-03-02
IL280139A (en) 2021-03-01
WO2020018970A1 (en) 2020-01-23
PH12020552155A1 (en) 2021-07-05
JP7411631B2 (ja) 2024-01-11

Similar Documents

Publication Publication Date Title
CL2021000152A1 (es) Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1
CO2021001530A2 (es) Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1
CO2019009036A2 (es) Compuestos químicos como inhibidores de la actividad de la interleuquina-1
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
CL2019001709A1 (es) Derivados pirazol como inhibidores de malt1.
CO2017006997A2 (es) Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
MX2022000711A (es) Inhibidores de parp1.
CO2020002588A2 (es) Composiciones que comprenden un inhibidor de shp2 y metodos para tratar el cáncer
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
NZ742819A (en) Inhibitors of cxcr2
CL2015002194A1 (es) Inhbidores de erk y sus usos
MA40076A (fr) Inhibiteurs de syk
CL2020000375A1 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
CU20200041A7 (es) Amidas de imidazopiridina sustituidas
CL2019002557A1 (es) Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1.
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
CL2019001397A1 (es) Estabilidad mejorada de composiciones que contienen inhibidor de la ureasa.
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
TN2017000465A1 (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
CO2022000260A2 (es) Inhibidores de la autofagia de la amida aminopirimidina y sus métodos de uso
CL2022003348A1 (es) Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios
CL2023001637A1 (es) Inhibidores de la vía jak1 para el tratamiento del vitíligo.
AR113514A1 (es) Composiciones y métodos para mejorar la utilización del fósforo y el calcio en la dieta de los animales